Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen income Statement — Total revenues ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Income (DB)
Latest, Q2 2026
10,054
Period ended Jun 30, 2026
Change on a year earlier
+9.5%
9,179 in Q2 2025
History
61 quarters
Since Q2 2008
Sources
41
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up income statement — total revenues ($m)
- Cost of sales ($M)2,811 · Q2 2026
- Research and development expense ($M)1,868 · Q2 2026
- Selling, general and administrative expense ($M)1,745 · Q2 2026
- Advertising expense ($M)–
- Impairment charges ($M)-80 · Q4 2015
- Restructuring charges ($M)15 · Q4 2023
- Total operating expenses ($M)6,540 · Q2 2026
- Operating income ($M)3,514 · Q2 2026
- Interest expense, net ($M)673 · Q2 2026
- Interest and other income, net ($M)125 · Q2 2026
- Other nonoperating income (expense) ($M)-73 · Q2 2026
- Income before income taxes ($M)2,768 · Q2 2026
- Provision for income taxes ($M)393 · Q2 2026
- Net income ($M)2,375 · Q2 2026
- Earnings per share — Basic ($/sh)4.40 · Q2 2026
- Earnings per share — Diluted ($/sh)4.37 · Q2 2026
- Weighted-average basic shares (M)540 · Q2 2026
- Weighted-average diluted shares (M)544 · Q2 2026
- Dividends declared per share ($/sh)0 · Q2 2026
Cite this data
StockData. (2026). Amgen Income Statement — Total revenues ($M) ($M), quarterly Q2 2008–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fs_income_stmt
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.